UNSPSC 51192013: Oxipurinol or oxypurinol

This classification denotes a xanthine oxidase inhibitor with the molecular formula C5H4N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G97OZE5068, chemically known as 4,6-dihydroxypyrazolo(3,4-d)pyrimidine but generally known as oxipurinol, which bears US NIH Compound Identifier 4644. European Medicines Agency schedules Oxipurinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09535MIG.

The term OXIPURINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). OXIPURINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Oxipurinol or oxypurinol bears US NLM identifiers UMLS ID C0030086 and NCI Concept Code C87294. SMILES: O=C1[NH]C(=O)NC2[NH][NH]CC12.

UNSPSC 51192013 Oxipurinol or oxypurinol is a Commodity code that shows no relevant recent state and local procurement activity. The three most recent opportunities tagged under this code — athletic training services for fire and police departments (City of Tucson, RFP due June 9, 2026), medical aid supplies for a fire rescue department (City of Tampa, ITB due April 9, 2025), and a pharmacy benefit program information-gathering RFI (Texas Health and Human Services Commission, RFI closed April 3, 2026) — are entirely unrelated to oxipurinol, a uric acid-lowering pharmaceutical metabolite, and do not reflect actual procurement of this drug or any pharmaceutical product under the code's nominal scope.

The mismatch between the code's pharmaceutical designation and the services and supplies actually being solicited indicates that state and local procurement systems are tagging these opportunities incorrectly or that the code has been repurposed in this jurisdiction's taxonomy. Business development professionals should verify the correct UNSPSC code directly with the issuing bodies or their procurement systems before pursuing opportunities listed under this code, as the present record does not support any active market for oxipurinol procurement at the state or local level.